Surgical Results of Growth Hormone-Secreting Pituitary Adenoma
Authors:
Open Access
- 1 January 2009
- journal article
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 45 (5) , 271-274
Abstract
We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007. The patient group included 23 women and 19 men, with a mean age of 40.2 (range 13-61) years, and a mean follow-up duration of 49.4 (range 3-178) months after the operation. For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification. We analyzed the surgical results of the patients according to the most recent stringent criteria for cure. The overall rate of endocrinological remission in the group of 42 patients after primary TSS was 64% (26 of 42). The remission rate was 67% (8 of 12) for microadenoma and 60% (18 of 30) for macroadenoma. The remission rate was 30% (3 of 10) for the group with cavernous sinus invasion and 72% (23 of 32) for the group with intact cavernous sinus. Cavernous sinus invasion in Knosp grade III and IV was significantly correlated with the remission rate. There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration. TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.Keywords
This publication has 27 references indexed in Scilit:
- Medical therapy: Options and usesReviews in Endocrine and Metabolic Disorders, 2007
- Management of acromegaly: Is there a role for primary medical therapy?Reviews in Endocrine and Metabolic Disorders, 2007
- Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View after More than 1,000 OperationsNeuroendocrinology, 2006
- A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 yearsSurgical Neurology, 2006
- Transsphenoidal Surgery for Acromegaly in Wales: Results Based on Stringent Criteria of RemissionThe Journal of Clinical Endocrinology & Metabolism, 2003
- Transsphenoidal Surgery for Acromegaly: Endocrinological Follow-up of 98 PatientsNeurosurgery, 2001
- Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1The Journal of Clinical Endocrinology & Metabolism, 1998
- Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapyJournal of Neurosurgery, 1998
- Determinants of clinical outcome and survival in acromegalyClinical Endocrinology, 1994
- Pituitary Adenomas with Invasion of the Cavernous Sinus SpaceNeurosurgery, 1993